AdAlta (ASX:1AD) Accounts Payable : A$0.73 Mil (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is AdAlta Accounts Payable?

AdAlta's Accounts Payable for the quarter that ended in Dec. 2023 was A$0.73 Mil.

AdAlta's quarterly Accounts Payable increased from Dec. 2022 (A$0.83 Mil) to Jun. 2023 (A$1.12 Mil) but then declined from Jun. 2023 (A$1.12 Mil) to Dec. 2023 (A$0.73 Mil).

AdAlta's annual Accounts Payable increased from Jun. 2021 (A$0.22 Mil) to Jun. 2022 (A$0.56 Mil) and increased from Jun. 2022 (A$0.56 Mil) to Jun. 2023 (A$1.12 Mil).

AdAlta Accounts Payable Historical Data

The historical data trend for AdAlta's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AdAlta Accounts Payable Chart

AdAlta Annual Data

Trend

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Accounts Payable

Get a 7-Day Free Trial

1.51

0.54

0.22

0.56

1.12

AdAlta Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Accounts Payable	Get a 7-Day Free Trial										1.22	0.56	0.83	1.12	0.73

AdAlta Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

AdAlta Accounts Payable Related Terms

Thank you for viewing the detailed overview of AdAlta's Accounts Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

AdAlta (ASX:1AD) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AdAlta Ltd (ASX:1AD) » Definitions » Accounts Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

2 Park Drive, Unit 15, Bundoora, VIC, AUS, 3083

Website

https://www.adalta.com.au

AdAlta Ltd is engaged in drug discovery and development company developing protein therapeutics, known as i-bodies, for treating a wide range of human diseases. The i-body candidate, AD-214, is being developed for the treatment of idiopathic pulmonary fibrosis and other fibrotic diseases, for which current therapies are sub-optimal. Its pipeline includes Fibrosis, and CAR-T cancer therapeutics.

AdAlta (ASX:1AD) Headlines

No Headlines